Jefferies Upgrades ALX Oncology Holdings to Buy, Raises Price Target to $18
Portfolio Pulse from Benzinga Newsdesk
Jefferies analyst Michael Yee has upgraded ALX Oncology Holdings (NASDAQ:ALXO) from Hold to Buy and increased the price target from $8 to $18, indicating a positive outlook on the company's stock.
December 08, 2023 | 11:27 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Jefferies has upgraded ALX Oncology Holdings to Buy from Hold and raised the price target to $18, suggesting a bullish stance on the stock's potential.
Analyst upgrades typically lead to a positive short-term reaction in the stock market as they reflect a professional and positive change in the outlook for the company. The doubling of the price target from $8 to $18 is a significant change that could influence investor sentiment and drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100